Lee Ainslie Aerie Pharmaceuticals Inc Transaction History

Maverick Capital LTD

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$7.02 - $13.33 $47,195 - $89,617	-6,723 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.32 - $16.63 $323,004 - $474,520	-28,534 Reduced 80.93%	6,723 $77,000
Q2 2021 Aug 16, 2021	SELL	$15.16 - $18.97 $49,558 - $62,012	-3,269 Reduced 8.49%	35,257 $564,000
Q1 2021 May 17, 2021	BUY	$13.12 - $20.9 $287,931 - $458,671	21,946 Added 132.36%	38,526 $688,000
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $151,209 - $240,244	16,580 New	16,580 $224,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Maverick Capital LTD, based on Form 13F filings with the SEC.

Stay updated on Maverick Capital LTD and Lee Ainslie with notifications on news.